Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18745755 | 0.87 | PARP1 (0.40) | TRPV1MMP12PARP1CYP11B1CYP11B2 | |
| SCHEMBL10283759 | 0.80 | MMP12 (0.49) | MMP12PARP1CYP11B1CYP11B2TP53 | |
| SCHEMBL18307151 | 0.76 | MMP12 (0.38) | MMP12PARP1CYP11B1CYP11B2MAPT | |
| SCHEMBL7958200 | 0.76 | MMP12 (0.38) | MMP12PARP1CYP11B1CYP11B2MAPT | |
| SCHEMBL3082129 | 0.76 | ALDH1A1 (0.38) | MMP12PARP1CYP11B1CYP11B2MAPT | |
| SCHEMBL15979057 | 0.76 | NR3C2 (0.39) | MMP12CYP11B1CYP11B2NR3C2 | |
| SCHEMBL859012 | 0.76 | MMP12 (0.38) | MMP12PARP1CYP11B1CYP11B2MAPT | |
| SCHEMBL22521449 | 0.76 | TRPV1 (0.41) | TRPV1MMP12PARP1CYP11B1CYP11B2 | |
| SCHEMBL22521575 | 0.76 | NR3C2 (0.40) | TRPV1MMP12PARP1CYP11B1CYP11B2 | |
| SCHEMBL18352011 | 0.76 | NR3C2 (0.42) | TRPV1MMP12PARP1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8735418-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | TRPV1 3626/4885MMP12 3788/4885PARP1 1671/4885 |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | TRPV1 3626/4885MMP12 3788/4885PARP1 1671/4885 |
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | TRPV1 3359/4885MMP12 4057/4885PARP1 883/4885 |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | TRPV1 3653/4885MMP12 4303/4885PARP1 866/4885 |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | TRPV1 3740/4885MMP12 4363/4885PARP1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.